What is the fair value of Burzynski Research (OTC-BZYR) stock?

The current fair value estimate for Burzynski Research (OTC-BZYR) is $0.0047. This implies an estimated downside of 19.0% versus the current market price.

Is Burzynski Research (OTC-BZYR) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 19.0% versus the current market price.

How is the financial health of Burzynski Research?

The current financial health read for Burzynski Research (OTC-BZYR) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

Does Burzynski Research (OTC-BZYR) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Burzynski Research (OTC-BZYR)?

The current P/E ratio listed for Burzynski Research (OTC-BZYR) is -0.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Burzynski Research?

The current market capitalization listed for Burzynski Research is 761.086 K.

What is the enterprise value of Burzynski Research?

The current enterprise value listed for Burzynski Research is 760.235 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Burzynski Research?

The ticker symbol for Burzynski Research is OTC-BZYR, and the stock is listed on OTC Markets.

Where is Burzynski Research (OTC-BZYR) listed?

Burzynski Research (OTC-BZYR) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Burzynski Research?

The current debt-to-total-capital ratio listed for Burzynski Research is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Burzynski Research?

The free float listed for Burzynski Research is 19.0%. Free float helps investors understand how much of the share base is available for public trading.

Burzynski Research (BZYR) Fair Value & Stock Analysis

Q: What is the analyst price target for OTC-BZYR stock?

An analyst price target for Burzynski Research (OTC-BZYR) is not currently available in the latest data file.

Burzynski Research (BZYR)

Burzynski Research Institute, Inc. is a biotechnology company focused on the research and development of antineoplaston drugs for the treatment of various cancers. Under the Antineoplastons name, the company works with medical chemical compounds that include growth-inhibiting peptides, amino acid derivatives, and organic acids. Its activities also include research, production, marketing, promotion, and sale of these compounds, along with consulting services. Founded in 1977, the company is headquartered in Houston, Texas. Burzynski Research common stock trades on OTC Markets under the symbol BZYR.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-BZYR	$0.0047	-19.0% Downside	Overvalued	—	—	—	Weak	—	—	—	0.0%	—	-0.6x	-11.3x	—	761.086 K	760.235 K	0.0%	19.0%	-82,548.2	—	20.0%

Send a message